Benzinga · Aug 28, 2026
Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
-SEC Filing
AD
NASDAQ · ADIL
Adial Pharmaceuticals, Inc.
Healthcare · Biotechnology
$5.93
Up+$0.07 (+1.10%)
Updated Sep 11, 2026, 1:40 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.43M
- P/E ratio
- -0.28
- Dividend yield
- 0.00%
- 52-week range
- $1.31 – $10.75
- Volume
- 48.67K
- Avg. volume
- 28.85K
Price performance
ADIL price history
1M range · 19 trading sessions · Daily adjusted prices
ADIL closed at $5.93 after 19 trading sessions, up 35.08% for the selected period.
- Last close
- $5.93
- Period change
- +35.08%
- Period low
- $3.98
- Period high
- $7.12
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $6.64 | $6.65 | $5.87 | $5.93 | 48.67K |
| Sep 8, 2026 | $7.01 | $7.20 | $6.33 | $6.65 | 67.62K |
| Sep 4, 2026 | $6.61 | $7.20 | $6.27 | $7.12 | 50.25K |
| Sep 3, 2026 | $6.32 | $6.80 | $6.25 | $6.66 | 52.8K |
| Sep 2, 2026 | $5.92 | $6.43 | $5.80 | $6.32 | 53.79K |
| Sep 1, 2026 | $5.80 | $6.17 | $5.51 | $5.95 | 44.61K |
| Aug 31, 2026 | $5.57 | $5.98 | $5.30 | $5.75 | 69.91K |
| Aug 28, 2026 | $5.70 | $5.7899 | $5.45 | $5.60 | 63.52K |
| Aug 27, 2026 | $5.96 | $5.96 | $5.45 | $5.69 | 53.65K |
| Aug 26, 2026 | $5.84 | $6.07 | $5.5905 | $5.94 | 64.63K |
| Aug 25, 2026 | $5.35 | $5.90 | $5.1901 | $5.82 | 32.14K |
| Aug 24, 2026 | $6.19 | $6.19 | $4.70 | $5.40 | 133.3K |
| Aug 21, 2026 | $5.95 | $6.41 | $5.74 | $6.215 | 81.99K |
| Aug 20, 2026 | $5.81 | $5.94 | $5.36 | $5.90 | 42K |
| Aug 19, 2026 | $5.44 | $5.80 | $5.41 | $5.755 | 83.94K |
| Aug 18, 2026 | $4.82 | $5.55 | $4.73 | $5.45 | 125.82K |
| Aug 17, 2026 | $3.84 | $5.08 | $3.84 | $4.99 | 146.19K |
| Aug 14, 2026 | $4.11 | $4.37 | $3.98 | $3.98 | 48.59K |
| Aug 13, 2026 | $4.35 | $4.64 | $4.26 | $4.39 | 52.09K |
Latest ADIL news
The latest Smart Investors Daily articles mentioning ADIL.
Stock researchCompany · Overview
ADIL research
Overview
Company profile and research snapshot.
Company profile
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 3, 2026 | Alliance Global Partners | Buy | — |
| Jun 15, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Sep 30, 2025 | Maxim Group | Buy | — |
| Nov 14, 2024 | Rodman & Renshaw | Buy | — |
| Jul 11, 2023 | Brookline Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 25, 2026
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
GLEN ALLEN, Va., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 307,814 shares of common stock as an inducement to such person becoming an employee of the Company. The option award has an exercise price of $5.76 per share, the closing price of the Company’s common stock on August 19, 2026, the effective date of grant and has a ten-
Benzinga · Aug 24, 2026
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares increased by
Benzinga · Aug 17, 2026
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved upwards by
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
